China's 1H25 Innovative Drug Out-Licensing Deal Value Exceeds USD100 Billion, Hitting New HighAASTOCKS News·Jul 20 at 01:00 AM510660+0.86%159992+1.57%
Chinese biotech overtakes AI as emerging-market growth tradeBusinesstimes News·Jul 26 at 10:14 PM300765+5.61%AZN-1.13%
China's Humanoid Robot Products Exceed 400 Models, Accounting for Over Half of Global TotalAASTOCKS News·Jul 20 at 01:00 AM513060+0.38%159859+1.32%
10:30 ETSingle-use Bioreactors Market worth $9.58 billion by 2031 - Exclusive Report by MarketsandMarkets™prnewswire·Jul 23 at 09:31 AMLABD-6.82%IBBQ+0.90%
BeOne Medicines CEO John Oyler reports disposal of shares worth $75.72 millionPUBT·Jul 17 at 04:31 PM06160-1.12%BGNE0.00%
SystImmune Announces Second Approval of Iza-bren in China for the Treatment of Recurrent or Metastatic Esophageal Squamous Cell CarcinomaUnusual Whales·Jul 17 at 07:27 AM688506-2.93%02615
Macquarie Raises BEONE MEDICINES TP to HKD257, Reiterates Outperform RatingAASTOCKS News·Jul 13 at 03:20 AMONC-1.57%06160-1.12%
China's Outbound Licensing of Innovative Drugs in First Half Nears Last Year's TotalYicai·Jul 13 at 02:28 AM159859+1.32%513700+0.35%
Analyst Reiterates Buy on BeiGene, Lifts Brukinsa-Driven Outlook and Raises Price Target to $380 Amid Pipeline ProgressTip Ranks·Jul 12 at 07:25 PM06160-1.12%688235-0.95%
Transthera wins China NMPA clearance for Phase II TT-00973 combo trial in EGFR-mutant NSCLCPUBT·Jul 10 at 09:18 AM688578-3.77%
Huafu Securities Sticks to Its Buy Rating for BeOne Medicines Ltd (6160)Tip Ranks·Jul 7 at 12:15 AMONC-1.57%BGNE0.00%
Guotai Asset Management flags China pharma re-rating as 2026 essential drugs list adds 165 medicinesPUBT·Jul 10 at 04:25 AM520690-0.28%520880-0.46%
The chip pullback is ushering in a bumpy market. These sectors are the best bets now, according to Morgan Stanley.Dow Jones·Jul 6 at 03:54 AMMS+3.41%SOXS-26.29%
China’s biotech boom: RAS-targeted drugs challenge US dominanceSCMP·Jul 8 at 03:05 AM01276-0.52%600276-1.04%
